ERY 974

Drug Profile

ERY 974

Alternative Names: Anti glypican3/CD3 bispecific antibody; ERY974; T cell redirecting bispecific antibody - Chugai

Latest Information Update: 06 Oct 2016

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Chugai Pharmaceutical
  • Class Antineoplastics; Bispecific antibodies; Monoclonal antibodies
  • Mechanism of Action CD3 antigen inhibitors; Glypican 3 inhibitors; Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Solid tumours

Most Recent Events

  • 01 Aug 2016 Phase-I clinical trials in Solid tumours in USA (IV) (NCT02748837)
  • 03 Jun 2016 Chugai plans a phase I trial for glypican3-positive Solid tumours
  • 29 Apr 2016 Preclinical trials in Solid tumours in Japan (IV) before April 2016
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top